Exploring JAK Inhibitors for Inflammatory Skin Disorders: Improving Outcomes for Alopecia Areata

CME: 1.5

Target Audience

This initiative is intended for US dermatology allied HCPs, including PAs, NPs, and nurses, as well as other allied HCPs who may be involved in the management of patients with AA .

Program Overview

Review of the clinical manifestations and assessment of Alopecia areata (AA), along with clinical trial results with oral JAK inhibitors, which are showing promise. This program has been created for US dermatology allied healthcare professionals (HCPs) and will include several interactive case study discussions.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the clinical manife, associated autoimmune disorders, and psychosocial burden of AA
  • Review the epidemiology and risk factors associated with AA
  • Identify immunologic pathways involved in the pathogenesis of AA
  • Explain the mechanism of action of emerging systemic therapies for AA, focusing on JAK inihibition
  • Assess the target specificity and benefits/risks of emerging JAK inhibitors and other drug classes for AA
  • Identify clinical considerations for the potential use of emerging therapies specific to AA 

Post a comment to this article